Literature DB >> 26153913

Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies.

T Tzellos1, C C Zouboulis2, W Gulliver3, A D Cohen4,5, P Wolkenstein6, G B E Jemec7.   

Abstract

Hidradenitis suppurativa (HS) is a chronic, inflammatory, debilitating skin disease. The aim of the study was to systematically review the literature and critically answer the question: In patients with HS, do cardiovascular risk factors appear at a significantly higher rate compared with controls? The main search was conducted in Medline, Embase and the Cochrane Central Register. Studies eligible for inclusion were of case-control, cross-sectional and cohort design, and included comparison of any cardiovascular risk factor(s) in patients with HS with those of control groups. An I(2) value > 50% was considered to show substantial heterogeneity. In this case, DerSimonian and Laird random-effect models were considered to compute pooled odds ratios (OR). Otherwise, a fixed-effects model was suitable. Nine studies, with 6174 patients with HS and 24 993 controls, were included. Significant association of HS with obesity [OR 3·45, 95% confidence interval (CI) 2·20-5·38, P < 0·001], central obesity (OR 2·97, 95% CI 1·41-6·25, P = 0·004), active smoking (OR 4·34, 95% CI 2·48-7·60, P < 0·001), history of smoking (OR 6·34, 95% CI 2·41-16·68, P < 0·001), hypertriglyceridemia (OR 1·67, 95% CI 1·14-2·47, P = 0·009), low high-density lipoprotein (HDL) (OR 2·48, 95% CI 1·49-4·16, P < 0·001), diabetes (OR 2·85, 95% CI 1·34-6·08, P = 0·007) and metabolic syndrome (OR 2·22, 95% CI 1·62-3·06, P < 0·001) was detected. Associations were significant both in population and hospital patients with HS, with hospital HS groups having uniformly higher ORs than the population HS groups. Causality could not be assessed. Heterogeneity was substantial in all analyses. This systematic review indicated that cardiovascular risk factors appear at a significantly higher rate in patients with HS compared with controls. The need for screening of patients with HS for modifiable cardiovascular risks is emphasized.
© 2015 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2015        PMID: 26153913     DOI: 10.1111/bjd.14024

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  27 in total

Review 1.  Hidradenitis Suppurativa: Causes, Features, and Current Treatments.

Authors:  Caroline Vinkel; Simon Francis Thomsen
Journal:  J Clin Aesthet Dermatol       Date:  2018-10-01

2.  Clinical manifestations and quality of life in hidradenitis suppurativa patients: survey of participants from an internet support group.

Authors:  Isabel Greco Tavora; Gabriela Cabral Bissoli; Hélio Amante Miot; Juliano Vilaverde Schmitt
Journal:  An Bras Dermatol       Date:  2019-07-29       Impact factor: 1.896

3.  Incidence of Myocardial Infarction and Cerebrovascular Accident in Patients With Hidradenitis Suppurativa.

Authors:  Sarah Reddy; Andrew Strunk; Gregor B E Jemec; Amit Garg
Journal:  JAMA Dermatol       Date:  2020-01-01       Impact factor: 10.282

4.  Disease Trajectories for Hidradenitis Suppurativa in the Danish Population.

Authors:  Rune Kjærsgaard Andersen; Isabella Friis Jørgensen; Roc Reguant; Gregor Borut Ernst Jemec; Søren Brunak
Journal:  JAMA Dermatol       Date:  2020-07-01       Impact factor: 10.282

5.  Association of autoimmune blistering disease, and specifically, pemphigus vulgaris, with cardiovascular disease and its risk factors: a systematic review and meta-analysis.

Authors:  Alex M Rokni; Marissa Ayasse; Adnan Ahmed; Lauren Guggina; Robert W Kantor; Jonathan I Silverberg
Journal:  Arch Dermatol Res       Date:  2022-03-09       Impact factor: 3.017

Review 6.  Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review.

Authors:  Nicolò Scuderi; Ambra Monfrecola; Luca Andrea Dessy; Gabriella Fabbrocini; Matteo Megna; Giuseppe Monfrecola
Journal:  Skin Appendage Disord       Date:  2017-03-21

7.  Diagnosis and management of hidradenitis suppurativa in women.

Authors:  Erin K Collier; Ram K Parvataneni; Michelle A Lowes; Haley B Naik; Martin Okun; Vivian Y Shi; Jennifer L Hsiao
Journal:  Am J Obstet Gynecol       Date:  2020-09-24       Impact factor: 8.661

Review 8.  Hidradenitis suppurativa/Acne inversa: an endocrine skin disorder?

Authors:  Ioannis Karagiannidis; Georgios Nikolakis; Robert Sabat; Christos C Zouboulis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 9.  Skin and metabolic syndrome: A review of the possible associations.

Authors:  Neda Adibi; Reza M Robati
Journal:  J Res Med Sci       Date:  2021-02-27       Impact factor: 1.852

Review 10.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.